

Anas N. Hajhussein,<sup>a</sup> Loay S. Abuzahra,<sup>a</sup> Anna Pietrzak,<sup>a,b</sup> Mary F. Sadek,<sup>a</sup> Muhammad O. Ali, <sup>a</sup> Jakub Wojciechowski,<sup>a</sup> Andrienne C. Friedli,\* <sup>a</sup> and Piotr Kaszyński\* <sup>a,c,d</sup>

 <sup>a</sup> Organic Materials Research Group, Department of Chemistry, Middle Tennessee State University, Murfreesboro, TN 37132, USA
<sup>b</sup> Łódź University of Technology, 90 924 Łódź, Poland
<sup>c</sup> Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, 90-363 Łódź, Poland
<sup>d</sup> Faculty of Chemistry, University of Łódź, 91 403 Łódź, Poland
Email: <u>Piotr.kaszynski@mtsu.edu</u>

**Received** 07-27-2018

**Accepted** 09-06-2018

Published on line 10-11-2018

#### Abstract

A series of 4-alkoxypyridines with n = 5–18 was obtained in typical yields of 75-80% by reacting 4-chloropyridine hydrochloride with the appropriate alcohol in DMSO in the presence of powdered NaOH. The reported synthesis is compared to other methods for preparation of 4-alkoxypyridines, and their uses are reviewed. 4-Tridecyloxypyridine is converted into the bis-zwitterionic derivative of [*closo*-B<sub>10</sub>H<sub>10</sub>]<sup>2-</sup>, which exhibits liquid crystalline and soft crystalline phases. The solid-state structures of two pyridines and the biszwitterion are established by the single crystal XRD method. The effect of *N*-atom coordination on the pyridine ring geometry is investigated.



Keywords: Pyridines, XRD, closo-borane, zwitterions, liquid crystals

#### Introduction

There is a rapidly growing interest in 4-alkoxypyridines 1[n] ( $n \ge 3$ ) as intermediates for soft materials such as liquid crystals<sup>1-5</sup> (including polar,<sup>6-11</sup> ionic<sup>12-15</sup> and quadrupolar species, such as  $2[n]^{10}$  in Figure 1), molecular electronics,<sup>16</sup> bio-active derivatives,<sup>17-19</sup> and also for research on organometallic complexes,<sup>2-4,20-22</sup> weak intermolecular interactions,<sup>1,5</sup> and various other aspects of organic chemistry.<sup>23-25</sup> Some 4-alkoxypyridines 1[n] have been shown to exhibit biological activity, such as inhibition of cytochrome P-450–catalyzed aniline hydroxylation<sup>26,27</sup> or gastric antisecretory activity.<sup>28</sup>



#### Figure 1. Structures of 1[n] and 2[n]

In most cases, 4-alkoxypyridines (**1**[**n**]) are *N*-substituted by reactions with metal-centered Lewis acids,<sup>2,3,20-22</sup> organic electrophiles,<sup>12,13,18,19,23,25</sup> or boron electrophiles.<sup>6,7,11</sup> In rare cases C-positions of the pyridine ring in **1**[**n**] are substituted before further transformations.<sup>16,24</sup>

In spite of the increasing use of 4-alkoxypyridines (**1**[**n**];  $\mathbf{n} \ge 3$ ), only a handful are well characterized (**1**[**3**],<sup>29,30</sup> **1**[**7**],<sup>6,7</sup> **1**[**8**],<sup>5,23</sup> **1**[**9**],<sup>7</sup> **1**[**10**],<sup>1,16</sup> **1**[**12**],<sup>5</sup> **1**[**16**]<sup>5</sup>), some have partial data (**1**[**4**],<sup>19,24,28</sup> **1**[**5**],<sup>7,28</sup> **1**[**8**]<sup>23</sup>, **1**[**16**]<sup>4</sup>), while others are only mentioned in the literature without any data (**1**[**6**]),<sup>20,27</sup> **1**[**14**],<sup>12</sup> **1**[**18**]<sup>12,22</sup>) and several homologs are not reported (e.g. **1**[**11**], **1**[**13**] and **1**[**15**]). Therefore, there is a need for a comprehensive approach to the synthesis of this series **1**[**n**] and complete characterization of its members.

The reported methods for synthesis of **1**[**n**] can be divided into two general categories: those using alkyl electrophiles and pyridine nucleophiles (Method A, Figure 2) and those using alkyl nucleophiles and pyridine electrophiles (Method B, Figure 2). In the first method, the most convenient pyridine precursor is 4-hydroxypyridine (**3**) (4-pyridone), which is deprotonated with a base and reacted with an alkyl halide **4**[**n**]. Due to the amphiphilic nature of the anion generated from **3**, a mixture of two isomeric products is formed, then separated by chromatography. This can be tedious and difficult for higher homologs. The method is relatively inexpensive and simple, but the ratio of the two isomers of the N– vs O–alkylated product depends on the reaction conditions. Thus, when the reaction is conducted with K<sub>2</sub>CO<sub>3</sub> in DMF at ambient temperature, **1**[**10**] is obtained in 70% yield,<sup>1</sup> **1**[**16**] in 89% yield,<sup>3</sup> and also **1**[**12**] was obtained under these conditions.<sup>21</sup> On the other hand, in MeCN solutions at reflux, the yield of **1**[**12**] was only 9%.<sup>31</sup> The same reaction conducted in a THF/aq NaOH system with [Bu<sub>4</sub>N]<sup>+</sup>Br<sup>-</sup> as a phase transfer catalyst gave the *N*-alkylated products isolated in yields 75-80%.<sup>12</sup>

Method B involves electrophilic pyridine derivatives with a leaving group at the C(4) position. The most useful reagent is 4-chloropyridine (5) or its hydrochloride (5·HCl), available from 4-hydroxypyridine (3). The alkoxide nucleophile is generated from the appropriate alcohol 6[n] typically by using  $Na^{22,25,29}$  or  $NaH^{24}$  in excess alcohol as the solvent (typically in lower boiling alcohols, but also 1[10]<sup>25</sup> and 1[18]<sup>22</sup> were obtained this way) or with NaH in dry DMSO.<sup>5-7,23</sup> There are also two reports of using NaOH in DMSO to generate the

alkoxide, but with no details provided.<sup>12,18</sup> In another modification, 4-chloropyridine (**5**) or 4-bromopyridine is reacted with excess propanol (**6[3]**),  $K_2CO_3$  and catalytic amounts of  $Zn(NO_3)_2 \cdot 6H_2O$  at 75 °C for 24 hours giving **1[3]** in 84% yield.<sup>30</sup> In some earlier literature, *N*-(pyrid-4-yl)pyridinium hydrochloride<sup>19</sup> and 4-phenoxypyridine<sup>32,33</sup> were reacted with RONa in excess alcohol to obtain some **1[n]**.

One main advantage of the method described here is the clean formation of a single product, the desired 4-alkoxypyridine (**1[n]**), which simplifies its isolation. The method can be more practical and less expensive without anhydrous conditions and using a less expensive base to generate the alkoxide.





Here we report the preparation of 12 members of a homologous series 1[n] (n = 5-18, Figure 2) using a modified method B in which powdered NaOH is used in reagent grade DMSO. All derivatives were completely characterized including two new 4-alkoxypyridines, 1[11] and 1[13]. We demonstrate application of the pyridines by preparing a bis-zwitteronic derivative 2[13]. We also report three molecular structures obtained by single crystal XRD methods.

# **Results and Discussion**

### Synthesis

A series of 4-alkoxypyridines 1[n] (n = 5-18) was obtained from 4-chloropyridine hydrochloride (5·HCl) and appropriate alcohol 6[n] in reagent grade DMSO (not dried) in the presence of finely divided NaOH (powder or sand, Scheme 1). The products were separated from the unreacted alcohol by short-path distillation ( $n \le 9$ ), Kugel-Rohr distillation (n = 10-12) or column chromatographic separation for higher members of the series. The typical isolated yields for 1[n] under the optimized conditions were in the range 75-80% based on the alcohol.



**Scheme 1**. Synthesis of derivatives **1**[**n**]. Reagents and conditions: *i*) NaOH powder or sand,  $4-ClC_5H_4N+HCl$  (**5-HCl**), ROH (**6**[**n**]), DMSO, 80 °C, 16 h.

Reaction conditions were optimized using **5·HCl** and nonanol (**6[9]**) on 5 or 10 mmol scale in 10 or 20 mL of DMSO. Initial experiments demonstrated that for stoichiometric amounts of reagents (1:1 ratio) and excess base, significant amounts of alcohol **6[n]** (20-30%) were unconsumed. This complicated separation of pure **1[n]**, especially for higher members of the series for which differences in the properties diminish with n. Therefore, it was decided to use excess **5·HCl**, which can be easily removed from the product either by aqueous work-up or by evaporation (as free base). It was established that full or nearly complete conversion ( $\geq$ 98%) of the alcohol requires 20% excess **5·HCl** added in two portions: 1.0 equiv at the beginning and 0.2 equiv after 0.5 h or later. Although for lower alcohols such as octanol the procedure is not economical due to the relatively high cost of **5·HCl**, it might be efficient for rare alcohols, such as optically active citronellol.

Experiments with various amounts of NaOH demonstrated that at least three equivalents per one equivalent of the alcohol is required and five equivalents is optimum for the reaction to be completed overnight at 80 °C. Monitoring progress of these test reactions with stoichiometric amounts of reagents (4·HCl : 6[9]: NaOH, 1:1:5) with <sup>1</sup>H NMR spectroscopy demonstrated that within the first hour about 33% of 1[9] is formed, which increases to 71% after an additional 2 h, but does not change significantly overnight.

Finally, the effect of temperature on reaction progress and the yield of the product were also briefly investigated using the <sup>1</sup>H NMR of the crude reaction mixture stirred overnight. For the test reaction (**5·HCl** : **6[9]**: NaOH, 1:1:5), the yield of **1[n]** or degree of conversion of 1-nonanol (**6[9]**), was 71% at 80 °C, 62% at 100 °C and only 43% at 120 °C. This suggests chemical instability of the pyridine ring under highly caustic conditions at elevated temperatures. On the other hand, below 80 °C the reaction proceeded very slowly.

The obtained pyridines **1**[**n**] have been used for the preparation of zwitterionic derivatives of *closo*boranes.<sup>7,10</sup> An example of such a synthesis is shown in Scheme 2. Thus, stirring of bis-phenyliodonium derivative **7** with excess pyridine **1**[**13**] used as the solvent at 80 °C led to bis-pyridinium derivative **2**[**13**] isolated by column chromatography in 51% yield.



Scheme 2. Synthesis of derivative 2[13]. Reagents and conditions: i) 4-C<sub>13</sub>H<sub>27</sub>OC<sub>5</sub>H<sub>4</sub>N (1[13]) neat, 80 °C, 12 h.

#### Molecular and crystal structures

Colorless crystals of **1[13]** and **1[16]** were obtained by slow evaporation of pentane solutions, while crystals of **2[13]** were grown from MeCN solutions. Their solid-state structures were determined by low temperature single crystal X-ray analysis and results are shown in Figures 3–5. Data collection and refinement details are provided in the Supplentary Material.<sup>34</sup>

The pyridine derivative **1[13]** forms monoclinic crystals with P21/n space group with four molecules in the unit cell. In contrast, **1[16]** and **2[13]** crystallize in a triclinic  $P^{\overline{1}}$  space group with a unit cell containing two molecules, as shown in Figure 3.

The molecular dimensions in **1[13]** and **1[16]** are typical for alkoxy groups and the pyridine ring. The molecules have essentially  $C_s$  symmetry: the alkoxy chains are in a nearly ideal all-*trans* conformation and coplanar with the pyridine ring (the interplanar angle between the alkoxy chain and the pyridine ring is 1.9° and 2.4°, respectively). The total molecular length measured as the N<sup>…</sup>C(13) and N<sup>…</sup>C(16) distance is 20.26 Å and 24.20 Å, respectively. Similar planar molecular geometry and dimensions are observed in the **1[10]** derivative.<sup>35</sup>



**Figure 3**. Unit cell packing diagram for **1[16]** viewed along the *ac* axis. Thermal ellipsoid diagram drawn at 50% probability and the numbering system according to the chemical structure. Pertinent molecular dimensions:  $N(1)-C(2) 1.344(1) \text{ Å}, C(2)-C(3) 1.379(1) \text{ Å}, C(3)-C(4) 1.397(1) \text{ Å}, C(5)-C(6) 1.382(1) \text{ Å}, C(6)-N(1) 1.341(1) \text{ Å}, C(4)-O 1.359(1) \text{ Å}, O-C_{Alkyl} 1.4433(9) \text{ Å}, C(4)-O-C_{Alkyl} 118.24(6)^{\circ}, C(6)-N(1)-C(2) 115.50(7)^{\circ}.$ 

The molecular dimensions of the bis-pyridinium derivative **2[13]** are similar to those reported for its three homologues.<sup>10</sup> In contrast to its homologues, the solid-state structure of **2[13]** shows no positional disorder and the alkoxy chains are in the all-*trans* conformation. Crystal packing forces impose a small angle between the planes of the alkoxy chain and the pyridine ring (19.7° and 18.6°), while the two pyridine rings are nearly

coplanar (6.8°). Overall, molecules of **2[13]** adopt an *S*-shape, which is similar to that found for its homologues.<sup>10</sup>

Molecules of **2[13]** are closely packed in the unit cell with maximum interactions of the local B–N dipole moments (the B(1)<sup>...</sup>N intermolecular distance is 5.940(1) Å).



**Figure 4**. Unit cell packing diagram for **2[13]**. Thermal ellipsoid diagram drawn at 50% probability and the numbering system according to the chemical structure. Pertinent molecular dimensions: B(1)<sup>...</sup>B(10) 3.625(2) Å, B–N 1.526(1) and 1.530(1), N(1)–C(2) 1.354(2) Å, C(2)–C(3) 1.369(1) Å, C(3)–C(4) 1.397(1) Å, C(4)–C(5) 1.397(1) Å, C(5)–C(6) 1.373(1) Å, C(6)–N(1) 1.349(1) Å, C(4)–O 1.339(1) Å, O–C<sub>Alkyl</sub> 1.453(1) Å, C(4)–O–C<sub>Alkyl</sub> 117.4(1)°, C(6)–N(1)–C(2) 118.1(1)°.

The availability of the molecular structures for **1[13]** and **2[13]** permits the assessment of the effect of coordination of the nitrogen atom on pyridine ring geometry. Thus, the C(2)–C(3) and C(4)–O bonds contract by about -0.01 and -0.02 Å, respectively, while other bonds expand by an average of +0.01 (Figure 5a). Also, the C–N–C angle expands by +2.6°. These changes are consistent with shifting electron density from the oxygen atom towards the nitrogen atom and distortion towards a quinoid structure with localized double bonds such as in *N*-alkylpyridones.<sup>12</sup> Similar results were obtained when structure of **2[13]** is compared to that of **1[16]**. The observed changes in bonding parallel those in <sup>1</sup>H NMR chemical shifts, which reflect not only electron density redistribution, but also magnetic anisotropy of the ring current in the {*closo*-B<sub>10</sub>} cluster (Figure 5b).



**Figure 5**. Effect of *N*-coordination on pyridine a) ring geometry b) NMR chemical shifts. The numbers represent the change a) in bond lengths ( $\Delta$ Å) and in angles ( $\Delta$ °) and b) NMR shifts ( $\Delta$ Å) from **1[13]** to **2[13]**.

### Liquid crystalline behavior

Thermal analysis of **2[13]** revealed rich polymorphism as shown in Figure 6. Upon heating, the sample undergoes stepwise melting through four polymorphs before transitions at 160 °C to a 21 K wide nematic phase (Figure 7). Analysis of the cooling curve shows small hysteresis of the transitions, which suggests the formation of soft-crystalline phases. On the basis of powder XRD analysis for **2[12]**,<sup>10</sup> the phase below the nematic phase can be assigned as a crystalline laminate phase, Lam<sub>Cr</sub>.



**Figure 6**. DSC trace of **2[13]**. Transition temperatures and enthalpies (in italics): Cr<sub>1</sub> 88 (*25.8*) Cr<sub>2</sub> 96 (*11.5*) Cr<sub>3</sub> 110 (*10.4*) X 115 (*12.7*) Lam<sub>Cr</sub> 162 (*4.1*) N 180 (*0.8*) I. The heating and cooling rates are 10 K min<sup>-1</sup>.



**Figure 7.** Optical textures in polarized light of a) nematic phase (N, 170 °C), b) lamellar crystalline phase, (Lam<sub>cr</sub>, 140 °C), c) an unidentified X phase (90 °C), and d) crystalline phase (Cr, 80 °C) for **2[13]** obtained on cooling for the same sample region.

### **Summary and Conclusions**

A simple and efficient procedure for the preparation of series of 4-alkoxypyridines **1**[n] was developed and demonstrated for 12 members of the series. Reaction conditions and isolation procedures were optimized and

all compounds were completely characterized using NMR, IR spectroscopy and MS spectrometry. The procedure is particularly useful for high value primary alcohols. Application of the pyridines was demonstrated by preparation of **2[13]**, a new homolog of the **2[n]** series. A comparison of solid-state structures demonstrated pyridine ring geometry alteration upon coordination of the nitrogen atom.

### **Experimental Section**

**General.** Reactions were carried out under Ar and subsequent manipulations were conducted in air. NMR spectra were obtained at 500 MHz (<sup>1</sup>H), 125 MHz (<sup>13</sup>C) and 160 MHz (<sup>11</sup>B) fields. Chemical shifts were referenced to the solvent (<sup>1</sup>H and <sup>13</sup>C: 7.26 ppm and 77.16 ppm for CDCl<sub>3</sub>)<sup>36</sup> or to an external sample of neat  $BF_3$ ·EtO in CDCl<sub>3</sub> set at 0 ppm. All reagents and solvents: 1-alkanols (**6**[**n**]), 4-chloropyridine hydrochloride (**5·HCl**) and DMSO, were obtained from Sigma-Aldrich and used as received. Finely divided NaOH (sand) was obtained from Loudwolf Industrial and Scientific and stored in a desiccator.

## General procedure for synthesis of 4-alkoxypyridines (1[n])

A 100 mL round bottom flask was flushed with argon and reagents added *via* funnel in the following order: finely divided sodium hydroxide (2.00 g, 50.0 mmol), alcohol **6**[n] (10.0 mmol), and reagent grade DMSO (12 mL). The mixture was heated with stirring to 80 °C under argon and 4-chloropyridine hydrochloride (**5·HCl**, 1.50 g, 10.0 mmol) was added with DMSO rinse (8 mL). After approximately 30 min, an additional portion of **5·HCl** (0.300 g, 2.0 mmol) was added. The reaction was stirred and heated overnight. Water was added (20 mL) and the mixture was extracted with EtOAc/hexane (1:1, 2 x 20 mL). The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and solvent was removed under reduced pressure. Lower members of the series **1**[n] were purified from traces of impurities and unreacted alcohol by short-path distillation ( $n \le 9$ ) or Kugel-Rohr distillation (n = 10-12), while higher members of the series **1**[n] (n > 12) were purified by column chromatography using silica gel with gradient EtOAc/hexanes mixtures (starting from 5% up to 25% EtOAc) as eluent. Typical yields of isolated and purified products as colorless liquids or solids are in a range 75-80%. All 4-alkoxypyridines **1**[n] exhibit the following characteristic IR vibrations: (neat) v 1595, 1571, 1473, 1286, 1216, 1022, 820 cm<sup>-1</sup>.

**4-Tridecyloxypyridine** (**1[13]**). Mp 34-36 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.88 (t, *J* 6.9 Hz, 3H), 1.24-1.35 (m, 18H), 1.45 (quint, *J* 7.4 Hz, 2H), 1.79 (quint, *J* 7.2 Hz, 2H), 3.99 (t, *J* 6.6 Hz, 2H), 6.79 (dd, *J*<sub>1</sub> 4.8 Hz, *J*<sub>2</sub> 1.5 Hz, 2H), 8.40-8.42 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 14.2, 22.8, 26.0, 28.9, 29.4, 29.4, 29.6, 29.6, 29.7 (2C), 29.7, 32.0, 67.9, 110.3, 151.1, 165.1. Anal. Calcd. for C<sub>18</sub>H<sub>31</sub>NO: C, 77.92; H, 11.26; N, 5.05. Found: C, 77.86; H, 11.40; N, 4.97 %.

Analytical data for other derivatives **1**[**n**] are provided in the Supporting Information.

**Preparation of [closo-B<sub>10</sub>H<sub>8</sub>-1,10-(NC<sub>5</sub>H<sub>4</sub>OC<sub>13</sub>H<sub>17</sub>)<sub>2</sub>] (2[13]).** A mixture of [*closo*-B<sub>10</sub>H<sub>8</sub>-1,10-(IPh)<sub>2</sub>]<sup>37</sup> (**7**, 200 mg, 0.39 mmol) and 4-tridecyloxypyridine (**1[13]**), 1.5 mL) was stirred at 80 °C overnight. The mixture was separated by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/hexane, 3:2) providing 133.5 mg (51% yield) of biszwitterion **2[13]** as the fluorescent fraction. The product was recrystallized four times from an MeCN/EtOH mixture to obtain 102 mg (39% yield) of higly purified product: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ br m, 8H), 0.89 (t, *J* 6.9 Hz, 6H), 1.25–1.40 (m, 36H), 1.47–1.54 (m, 4H), 1.90 (quint, *J* 7.2 Hz, 4H), 4.22 (t, *J* 6.6 Hz, 4H), 7.12 (d, *J* 7.5 Hz, 4H), 9.34 (d, *J* 7.5 Hz, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 14.2, 22.8, 25.9, 28.7, 29.3, 29.5, 29.6, 29.7, 29.7, 29.8, 70.2, 111.7, 149.6, 168.7; <sup>11</sup>B NMR (160 MHz, CDCl<sub>3</sub>) δ -26.4 (d, *J* 120 Hz, 8B), 16.8 (s, 2B). Anal. Calcd. for C<sub>36</sub>H<sub>70</sub>B<sub>10</sub>N<sub>2</sub>O<sub>2</sub>: C, 64.43; H, 10.51; N, 4.17. Found: C, 64.67; H, 10.27; N, 4.21 %.

## Acknowledgements

This work was supported by the National Science Foundation (DMR-1611250 and XRD facility MRI-1626549) grants. We thank Dr. Rafał Jakubowski and Mr. Jessie Weatherly for technical assistance.

## References

1. Gonzalez, L.; Gimeno, N.; Tejedor, R. M.; Polo, V.; Ros, M. B.; Uriel, S.; Serrano, J. L. *Chem. Mater.* **2013**, *25*, 4503-4510.

https://doi.org/10.1021/cm401849f

 Deschenaux, R.; Donnio, B.; Rheinwald, G.; Stauffer, F.; Süss-Fink, G.; Velker, J. J. Chem. Soc., Dalton Trans. 1997, 4351-4355.

https://doi.org/10.1039/a704712f

- Abdullah, N.; Mohd Said, S.; Halid, Y. Y.; Megat Hasnan, M. M. I.; Sharmin, N.; Mat Hussin, S. A.; Nik Ibrahim, N. M. J.; Nordin, A. R.; Safiin, N. A.; Anuar, N. S. *J. Coord. Chem.* 2016, *69*, 2954-2971. <u>https://doi.org/10.1080/00958972.2016.1221504</u>
- Abdullah, N.; Sharmin, N.; Ozair, L. N.; Nordin, A. R.; Mohd Nasir, W. S. N.; Mohamadin, M. I. J. Coord. Chem. 2015, 68, 1347-1360. <u>https://doi.org/10.1080/00958972.2015.1016428</u>
- 5. Lin, H.-C.; Shiaw, J.-M.; Liu, R.-C.; Tsai, C.; Tso, H.-H. *Liq. Cryst.* **1998**, *25*, 277-283. <u>https://doi.org/10.1080/026782998206434</u>
- Kaszynski, P.; Huang, J.; Jenkins, G. S.; Bairamov, K. A.; Lipiak, D. Mol. Cryst. Liq. Cryst. 1995, 260, 315-332. https://doi.org/10.1080/10587259508038705
- Jankowiak, A.; Baliński, A.; Harvey, J. E.; Mason, K.; Januszko, A.; Kaszyński, P.; Young, V. G., Jr.; Persoons, A. J. Mater. Chem. C 2013, 1, 1144-1159. <u>https://doi.org/10.1039/C2TC00547F</u>
- 8. Ringstrand, B.; Kaszynski, P. *J. Mater. Chem.* **2010**, *20*, 9613-9615. <u>https://doi.org/10.1039/c0jm02876b</u>
- Pecyna, J.; Denicola, R. P.; Gray, H. M.; Ringstrand, B.; Kaszynski, P. *Liq. Cryst.* 2014, *41*, 1188-1198. <u>https://doi.org/10.1080/02678292.2014.911371</u>
- Ali, M. O.; Pociecha, D.; Wojciechowski, J.; Novozhilova, I.; Friedli, A. C.; Kaszyński, P. J. Organomet. Chem. 2018, 865, 226–233. https://doi.org/10.1016/j.jorganchem.2018.04.003
- 11. Pecyna, J.; Ringstrand, B.; Domagała, S.; Kaszyński, P.; Woźniak, K. *Inorg. Chem.* **2014**, *53*, 12617-12626. https://doi.org/10.1021/ic502265g
- 12. Lu, J.-T.; Lee, C.-K.; Lin, I. J. B. *Soft Matter* **2011**, *7*, 3491-3501. https://doi.org/10.1039/c0sm01376e
- 13. Ringstrand, B.; Monobe, H.; Kaszynski, P. *J. Mater. Chem.* **2009**, *19*, 4805-4812. <u>https://doi.org/10.1039/b905457j</u>
- 14. Jankowiak, A.; Sivaramamoorthy, A.; Pociecha, D.; Kaszyński, P. *RSC Adv.* **2014**, *4*, 53907-53914. <u>https://doi.org/10.1039/C4RA06502F</u>

- Ringstrand, B.; Jankowiak, A.; Johnson, L. E.; Pociecha, D.; Kaszynski, P.; Pociecha, D.; Gorecka, E. *J. Mater. Chem.* 2012, *22*, 4874-4880. https://doi.org/10.1039/c2jm15448j
- Zych, D.; Kurpanik, A.; Slodek, A.; Maroń, A.; Pająk, M.; Szafraniec-Gorol, G.; Matussek, M.; Krompiec, S.; Schab-Balcerzak, E.; Kotowicz, S.; Siwy, M.; Smolarek, K.; Maćkowski, S.; Danikiewicz, W. Chem. Eur. J. 2017, 23, 15746-15758.

https://doi.org/10.1002/chem.201703324

- Hay, D. A.; Rogers, C. M.; Fedorov, O.; Tallant, C.; Martin, S.; Monteiro, O. P.; Müller, S.; Knapp, S.; Schofield, C. J.; Brennan, P. E. *MedChemComm* **2015**, *6*, 1381-1386. <u>https://doi.org/10.1039/C5MD00152H</u>
- Chen, P.; Chaikuad, A.; Bamborough, P.; Bantscheff, M.; Bountra, C.; Chung, C.-w.; Fedorov, O.; Grandi, P.; Jung, D.; Lesniak, R.; Lindon, M.; Müller, S.; Philpott, M.; Prinjha, R.; Rogers, C.; Selenski, C.; Tallant, C.; Werner, T.; Willson, T. M.; Knapp, S.; Drewry, D. H. J. Med. Chem. 2016, 59, 1410-1424. https://doi.org/10.1021/acs.jmedchem.5b00209
- 19. Renshaw, R. R.; Conn, R. C. J. Am. Chem. Soc. **1937**, 59, 297-301. https://doi.org/10.1021/ja01281a021
- 20. Blight, B. A.; Wisner, J. A.; Jennings, M. C. *Inorg. Chem.* **2009**, *48*, 1920-1927. <u>https://doi.org/10.1021/ic801725u</u>
- 21. Yin, S.; Sun, H.; Yan, Y.; Zhang, H.; Li, W.; Wu, L. *J. Colloid Interfac. Sci.* **2011**, *361*, 548-555. <u>https://doi.org/10.1016/j.jcis.2011.06.006</u>
- Alea-Reyes, M. E.; González, A.; Calpena, A. C.; Ramos-López, D.; de Lapuente, J.; Pérez-García, L. J. Colloid Interfac. Sci. 2017, 502, 172-183. https://doi.org/10.1016/j.jcis.2017.04.064
- 23. Schmid, G. H.; Wolkoff, A. W. *Can. J. Chem.* **1972**, *50*, 1181-1187. <u>https://doi.org/10.1139/v72-185</u>
- 24. Maeda, C.; Kamada, T.; Aratani, N.; Sasamori, T.; Tokitoh, N.; Osuka, A. *Chem. Eur. J.* **2009**, *15*, 9681-9684. <u>https://doi.org/10.1002/chem.200901475</u>
- 25. Alcalde, E.; Pérez-García, L.; Dinarés, I.; Frigola, J. J. Org. Chem. **1991**, *56*, 6516-6521. <u>https://doi.org/10.1021/jo00023a013</u>
- 26. Born, J. L.; Hadley, W. M. *J. Pharm. Sci.* **1980**, *69*, 465-466. <u>https://doi.org/10.1002/jps.2600690428</u>
- 27. Born, J. L.; Hadley, W. M. Proc. West. Pharmacol. Soc. **1980**, 23, 259-262.
- 28. Butler, D. E.; Bass, P.; Nordin, I. C.; Hauck, F. P., Jr.; L'Italien, Y. J. *J. Med. Chem.* **1971**, *14*, 575-579. <u>https://doi.org/10.1021/jm00289a005</u>
- 29. Koenigs, E.; Neumann, L. *Chem. Ber.* **1915**, *48*, 956-963. https://doi.org/10.1002/cber.191504801130
- 30. Abou-Shehada, S.; Teasdale, M. C.; Bull, S. D.; Wade, C. E.; Williams, J. M. J. ChemSusChem 2015, 8, 1083-1087.

https://doi.org/10.1002/cssc.201403154

- 31. Yang, Q.-Y.; Lehn, J.-M. *Angew. Chem. Int. Ed.* **2014**, *53*, 4572-4577. <u>https://doi.org/10.1002/anie.201400155</u>
- 32. Koenigs, E.; Greiner, H. *Chem. Ber.* **1931**, *64*, 1049-1056. https://doi.org/10.1002/cber.19310640518

- 33. Vompe, A. F.; Monich, N. V.; Meskhi, L. M. Russ. J. Org. Chem. 1974, 10, 1301-1306.
- 34. For details see Supplementary Material.
- 35. Wojciechowski, J.; Kaszynski, P.; Friedli, A. C. CCDC # 1828912.
- 36. Fulmer, G. R.; Miller, A. J. M.; Sherden, N. H.; Gottlieb, H. E.; Nudelman, A.; Stoltz, B. M.; Bercaw, J. E.; Goldberg, K. I. Organometallics **2010**, 29, 2176–2179. <u>https://doi.org/10.1021/om100106e</u>
- 37. Kaszynski, P.; Ringstrand, B. *Angew. Chem. Int. Ed.* **2015**, *54*, 6576-6581. <u>https://doi.org/10.1002/anie.201411858</u>